BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...small cap group, Muijrers' picks include cardiovascular and oncology company BioInvent International AB (SSE:BINV) and Laboratorios Farmaceuticos Rovi S.A....
...Francisco, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Apr 5, 2010
Company News

Laboratorios Farmaceuticos Rovi S.A., Novartis deal

...related to the production of egg- and cell culture-derived vaccines. Further terms were not disclosed. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Finance

Regulatory milestones

...the company terminated an agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Analyst Picks & Changes

Analyst picks & changes

...and removed EU vaccine sales revenues from his model after Novavax ended negotiations to grant Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Company News

Laboratorios Farmaceuticos Rovi, Novavax deal

...continue to seek partners for its vaccine technology in Europe (see BioCentury, July 6, 2009). Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 9, 2010
Company News

Novavax terminates vaccine deal in Spain

...Inc. (NASDAQ:NVAX) terminated an agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Jul 6, 2009
Company News

Novavax, Laboratorios Farmaceuticos Rovi deal

...are finalized and are expected to include milestones and royalties. Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Jul 6, 2009
Finance

Ebb & Flow

...after announcing an initial agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos ROVI S.A....
BioCentury | Jul 1, 2009
Company News

Novavax gains on vaccine deal

...after announcing an initial agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos ROVI S.A....
Items per page:
1 - 9 of 9
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Flavored with Phase III

...small cap group, Muijrers' picks include cardiovascular and oncology company BioInvent International AB (SSE:BINV) and Laboratorios Farmaceuticos Rovi S.A....
...Francisco, Calif. Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Apr 5, 2010
Company News

Laboratorios Farmaceuticos Rovi S.A., Novartis deal

...related to the production of egg- and cell culture-derived vaccines. Further terms were not disclosed. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Finance

Regulatory milestones

...the company terminated an agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Analyst Picks & Changes

Analyst picks & changes

...and removed EU vaccine sales revenues from his model after Novavax ended negotiations to grant Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 15, 2010
Company News

Laboratorios Farmaceuticos Rovi, Novavax deal

...continue to seek partners for its vaccine technology in Europe (see BioCentury, July 6, 2009). Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Feb 9, 2010
Company News

Novavax terminates vaccine deal in Spain

...Inc. (NASDAQ:NVAX) terminated an agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Jul 6, 2009
Company News

Novavax, Laboratorios Farmaceuticos Rovi deal

...are finalized and are expected to include milestones and royalties. Novavax Inc. (NASDAQ:NVAX), Rockville, Md. Laboratorios Farmaceuticos Rovi S.A....
BioCentury | Jul 6, 2009
Finance

Ebb & Flow

...after announcing an initial agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos ROVI S.A....
BioCentury | Jul 1, 2009
Company News

Novavax gains on vaccine deal

...after announcing an initial agreement to license its recombinant virus-like particle (VLP) vaccine technology to Laboratorios Farmaceuticos ROVI S.A....
Items per page:
1 - 9 of 9